Date: 13th June 2019
The adoption of new technologies to accelerate drug discovery is key to success in the pharmaceutical world. Functional genomics has huge potential in this area and CRISPRs are becoming a dominant tool.
GlaxoSmithKline plc have now teamed up with the University of California to advance genomic research and improve drug discovery through the establishment of a state of the art Laboratory for Genomic Research (LGR). The aim is to bring together pioneers of CRISPR technology to help unravel the relationship of genes and disease and how to advance medicine. Located in San Francisco the lab will focus on immunology, oncology and neuroscience and bring together AI and machine learning. It is hoped that bringing together these advanced techniques will create the next generation of technologies that will become the future standard for the pharmaceutical industry.
